Additionally, the patients with IPSS-defined high risk MDS are however already at very high risk of dying so the mutation in TP53 may not represent the most critical risk factor thus supporting the potential roles for other predictive factors of AZA response such as the CDKN2A and KDM6A variants seen in our study (Figure 6, Table 1). The gene discussed is CDKN2A; the disease is myelodysplastic syndrome.